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Introduction
Autophagy is a conserved process of “self-eating” of both proteins 
and cell organelles. This process is triggered as an adaptation to 
cellular stress, which is caused by several factors, such as starva-
tion, hypoxia, oxidative stress and DNA damage. Autophagy is 
initiated when the autophagosome, a double-membrane vesicle, 
engulfs cytoplasmic organelles. Autophagosomes fuse with lyso-
somes, which digests the vesicle’s contents.1 If excessive numbers 
of autophagic vacuoles accumulate, programmed cell death may 
be initiated.1
The complex role of autophagy in tumorigenesis has led 
many researchers to recognize that autophagy exhibits both 
tumor-promoting, as well as tumor-suppressing, activities.2-5 To 
previously, we proposed a new paradigm to explain the compartment-specific role of autophagy in tumor metabolism. In 
this model, autophagy and mitochondrial dysfunction in the tumor stroma promotes cellular catabolism, which results in 
the production of recycled nutrients. these chemical building blocks and high-energy “fuels” would then drive the anabolic 
growth of tumors, via autophagy resistance and oxidative mitochondrial metabolism in cancer cells. We have termed this 
new form of stromal-epithelial metabolic coupling: “two-compartment tumor metabolism.” Here, we stringently tested 
this energy-transfer hypothesis, by genetically creating (1) constitutively autophagic fibroblasts, with mitochondrial 
dysfunction or (2) autophagy-resistant cancer cells, with increased mitochondrial function. Autophagic fibroblasts 
were generated by stably overexpressing key target genes that lead to AMp-kinase activation, such as DRAM and LKB1. 
Autophagy-resistant cancer cells were derived by overexpressing GoLpH3, which functionally promotes mitochondrial 
biogenesis. As predicted, DRAM and LKB1 overexpressing fibroblasts were constitutively autophagic and effectively 
promoted tumor growth. We validated that autophagic fibroblasts showed mitochondrial dysfunction, with increased 
production of mitochondrial fuels (L-lactate and ketone body accumulation). Conversely, GoLpH3 overexpressing breast 
cancer cells were autophagy-resistant, and showed signs of increased mitochondrial biogenesis and function, which 
resulted in increased tumor growth. thus, autophagy in the tumor stroma and oxidative mitochondrial metabolism 
(oXpHoS) in cancer cells can both dramatically promote tumor growth, independently of tumor angiogenesis. For the 
first time, our current studies also link the DNA damage response in the tumor microenvironment with “Warburg-like” 
cancer metabolism, as DRAM is a DNA damage/repair target gene.
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resolve this long-standing paradox, our laboratory has offered 
a new model to better explain the compartment-specific role of 
autophagy in tumor progression. In this simplistic model, we 
have proposed autophagy acts as a tumor suppressor when it 
takes place in epithelial cancer cells; conversely, autophagy acts 
as a tumor promoter when it occurs in cancer-associated fibro-
blasts (CAFs).6
Our previous studies indicate that during tumor growth, can-
cer cells release reactive oxygen species (ROS) into the tumor 
microenvironment.7 This has been shown to initiate a loss of 
caveolin-1 (Cav-1) protein expression via the onset of autophagy 
and mitophagy in stromal fibroblasts.8,9 Subsequently, these 
autophagic cancer-associated fibroblasts, with reduced number 
of mitochondria, shift their metabolism toward glycolysis and 
produce high-energy mitochondrial fuels, including L-lactate, 
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show a loss of p53-dependent autophagy. Moreover, DRAM 
expression was found to be silenced by hyper-methylation at its 
CpG islands in multiple tumor types.24 Recently, other regulators 
of DRAM, such as p73, JNK and E2F1, have been identified.25-27
Another critical regulator of cellular stress and the autopha-
gic response is liver kinase B1 (LKB1), a serine/threonine kinase 
that is mutated in Peutz-Jeghers Syndrome.28 Peutz-Jeghers is rare 
autosomal-dominant harmatoma syndrome; carriers can also 
develop gastrointestinal, pancreatic and lung tumors.29 LKB1 
activates AMP-activated protein kinase (AMPK) by phosphory-
lation at the AMP-kinase theronine residue (T172). AMP-kinase 
functions as an energy sensor and tightly controls a variety of 
catabolic processes.28,30 In mammals, AMPK is a hetero-trimer 
consisting of three subunits: α (catalytic), β and γ (non-catalytic 
parts).31,32 Upon activation, AMPkinase induces autophagy via 
two main signaling pathways: (1) inhibition of the mammalian 
target of rapamycin-1 (mTOR1) complex, an autophagy inhibi-
tor, and (2) interaction with unc-51-like kinase 1 (ULK1), a key 
initiator of autophagy.28,33
GOLPH3/MIDAS/GPP34 is a mitochondrial protein which 
critically regulates mitochondrial lipid biogenesis and, hence, 
mitochondrial mass.34 It is normally upregulated in skeletal 
muscle cells in response to mitochondrial dysfunction as a com-
pensatory mechanism to promote mitochondrial biogenesis.34 
GOLPH3 shuttles between the Golgi apparatus and mitochon-
dria to increase the delivery of mitochondrial phospho-lipids 
(such as cardiolipin), thereby increasing overall mitochondrial 
mass.34 Recently, Scott et al. have found that GOLPH3 is ampli-
fied in multiple types of human cancer.35 Also, they proposed 
that GOLPH3 may function as an oncogene, via activation of the 
mTOR1 signaling pathway.35
Here, we genetically manipulated the expression of DRAM, 
LKB1 and GOLPH3 to dissect the compartment-specific role 
of autophagy and mitochondrial biogenesis in tumor growth. 
Autophagic fibroblasts, overexpressing DRAM or LKB1, showed 
AMP-kinase activation and promoted tumor growth in a para-
crine fashion that could not be accounted for by neo-vasculariza-
tion. In addition, autophagy-resistant cancer cells, overexpressing 
GOLPH3, showed mTOR-activation and an increase in mito-
chondrial function, resulting in a significant increase in tumor 
growth. Thus, our current results are consistent with the idea that 
(1) catabolism in the tumor microenvironment (e.g., autophagy 
and mitochondrial dysfunction) and (2) mitochondrial biogen-
esis/autophagy resistance in epithelial cancer cells, both enhance 
anabolic tumor growth.
In summary, autophagy functions as a tumor promoter or a 
tumor suppressor, depending on its compartmental or cellular 
localization. Our findings indicate that autophagy is a tumor 
promoter when it occurs in cancer-associated fibroblasts; con-
versely, autophagy functions as a tumor suppressor when it takes 
place in cancer cells.
This general model is also consistent with our previous find-
ings showing that activated HIF-1α (a major positive regulator of 
autophagy) functions as a tumor promoter in cancer-associated 
fibroblasts and as a tumor suppressor in epithelial cancer cells,36 
both independently of tumor angiogenesis.
ketone bodies (3-hydroxy-butyrate), glutamine and free fatty 
acids.10-12
Eventually, these secreted metabolites are consumed by 
neighboring cancer cells, which use these metabolites to “fuel” 
mitochondrial oxidative metabolism (OXPHOS).11,13 We have 
termed this energy-transfer model: (1) the “autophagic tumor 
stroma model of cancer” or (2) “two-compartment tumor 
metabolism”.11,14
Moreover, we and other laboratories have established that a 
loss of stromal caveolin-1 (Cav-1) expression in cancer-associated 
fibroblasts is a biomarker for poor prognosis in human breast 
and prostate cancers as well as in patients with melanoma.15-20 
As Cav-1 undergoes lysosomal degradation during autophagy 
in fibroblasts, a loss of stromal Cav-1 is a functional marker for 
autophagy, mitophagy and mitochondrial dysfunction in the 
tumor microenvironment.9 As stated above, this catabolic micro-
environment would then provide energy to sustain the anabolic 
growth of aggressive cancer cells, explaining its strong association 
with a poor prognosis.6,20,21
A key component of the cellular stress response is p53, which is 
mutated and/or deleted in > 50% of human cancers.22,23 Nuclear 
p53 can transactivate an array of autophagy inducers, such as 
damage-regulated autophagy modulator (DRAM).22 DRAM is 
a recently discovered lysosomal protein that is highly conserved 
and induces p53-dependent autophagy.24 DRAM-deficient cells 
Figure 1. DRAM-overexpressing fibroblasts show the induction of 
autophagy: Immunobotting. hteRt-BJ1 immortalized human fibro-
blasts were transduced with a lentiviral vector encoding DRAM, or the 
vector-alone control (Lv-105). After selection for puromycin resistance, 
the stable fibroblast cell lines were used to prepare protein lysates, 
which were then subjected to immunoblot analysis with specific 
antibody probes. (A) Immunoblot analysis validates the expression of 
DRAM. (B) Note that four autophagy markers (BNIp3, Beclin1, LAMp1 
and Cathepsin B) were all upregulated in response to DRAM expression, 
consistent with the induction of autophagy. In (A and B), immunoblot-
ting with β-actin is shown as a control for equal protein loading.
© 2012 Landes Bioscience.
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is also known to serve as a feed-forward mechanism for the induc-
tion of autophagy, perpetuating a vicious cycle of autophagy and 
mitochondrial dysfunction.
DRAM-overexpressing fibroblasts enhance tumor growth. 
We hypothesized that autophagic fibroblasts will actively pro-
mote tumor growth via the production of recycled nutrients and 
chemical building blocks derived from cellular catabolism. To 
test this hypothesis, DRAM-overexpressing fibroblasts were co-
injected with breast cancer cells (MDA-MB-231-GFP+) into the 
flanks of athymic nude mice flank. At 4 weeks post-injection, 
tumors grown in the presence of DRAM fibroblasts showed a 
~2-fold increase in tumor growth (as measured by either tumor 
weight or volume) (Fig. 6A).
To examine the possible contribution of angiogenesis to 
increase the tumor growth, we next immunostained frozen 
tumor sections with anti-CD31 antibodies, and then selected 
8–10 random fields from four tumors (of each experimental 
group) to quantify tumor vascularization. Although tumors 
grown with DRAM fibroblasts show a slight increase in vessel 
density (Fig. 6B), this small difference could not account for the 
observed 2-fold increase in tumor growth.
Thus, our data are more consistent with the hypothesis that 
catabolism in the tumor stroma can “fuel” the anabolic growth of 
cancer cells, via stromal-epithelial metabolic coupling.
LKB1-mediated AMP-kinase activation in cancer-associated 
fibroblasts drives autophagy and promotes tumor growth. AMP 
kinase is a master regulator of cell metabolism.28 AMP-kinase 
activation triggers numerous catabolic pathways, such as glycoly-
sis, autophagy and mitophagy. LKB1 is an upstream kinase that 
directly phosphorylates AMP kinase, resulting in its activation, 
Results
DRAM activates autophagy in fibro-
blasts, resulting in a loss of Cav-1 
protein expression and mitochondrial 
dysfunction, driving AMP-kinase acti-
vation. We previously established that a 
loss of caveolin-1 (Cav-1) in the tumor 
stroma correlates with poor prognosis 
in human breast cancers. Interestingly, 
genome-wide transcriptional profiling 
of Cav-1-deficient tumor stroma reveals 
the induction of an autophagic program. 
Thus, one hypothesis is that autophagic 
fibroblasts may enhance tumor growth.
To test this hypothesis directly, we 
generated fibroblasts with a constitutive 
autophagic phenotype. For this purpose, 
we chose to use DRAM (damage-regu-
lated autophagy modulator) to upregu-
late autophagy in stromal fibroblasts. 
DRAM is a lysosomal protein that is 
trans-activated by p53 and is critical for 
p53-dependent autophagy.
Briefly, immortalized human fibro-
blasts (hTERT-BJ1 cells) were sta-
bly transfected with DRAM (Fig. 1A). Then, we examined 
the expression of a panel of autophagy markers in DRAM-
overexpressing fibroblasts. Figure 1B shows that four autophagy 
markers (BNIP3, Beclin1, LAMP1 and Cathepsin B) were all 
upregulated in response to DRAM expression, consistent with 
the induction of autophagy. Similar results were also obtained 
when fibroblasts were co-cultured with human breast cancer cells 
(MDA-MB-231-GFP+); DRAM-expressing fibroblasts clearly 
showed increased expression of autophagy markers (LAMP1 and 
Beclin1) by immuno-fluorescence (Fig. 2). Importantly, DRAM-
overexpressing fibroblasts also showed a loss of Cav-1 expression 
as predicted, likely due to the induction of autophagy (Fig. 3).
As BNIP3 is a marker of mitophagy, we also investi-
gated the status of mitochondrial OXPHOS (complexes I–V). 
Interestingly, DRAM-overexpressing fibroblasts showed signifi-
cant reductions in components of complex I, III and IV (Fig. 4A) 
by immunoblotting, consistent with a mitophagy phenotype. 
Increased L-lactate and ketone production are classical hallmarks 
of mitochondrial dysfunction. Similarly, DRAM-overexpressing 
fibroblasts showed dramatic increases in L-lactate (> 3-fold) and 
β-hydroxy-butyrate (~3–5-fold) production, which was further 
accentuated by starvation (Fig. 4B–D).
Since mitochondrial dysfunction leads to increases in AMP 
levels (due to decreased ATP), we checked the status of AMP-
kinase activation. Figure 5 shows that AMP kinase is indeed 
hyperactivated in DRAM-overexpressing fibroblasts, indicative 
of a loss of mitochondrial function.
Thus, DRAM fibroblasts show the induction of autophagy, 
mitophagy and mitochondrial dysfunction with AMP-kinase 
activation. Consistent with our findings, AMP-kinase activation 
Figure 2. DRAM-overexpressing fibroblasts show the induction of autophagy: Immuno-fluores-
cence during co-culture. DRAM-overexpressing fibroblasts or the corresponding vector-alone con-
trol fibroblasts (Lv-105) were co-cultured with MDA-MB-231-GFp+ cells (GReeN) for a period of 3 d. 
Note that DRAM-expressing fibroblasts clearly showed increased expression of autophagy markers 
(LAMp1 and Beclin1) by immuno-fluorescence microscopy (red, indicated by white arrows). Nuclei 
were visualized by counter-staining with Hoechst-33258 (blue).
© 2012 Landes Bioscience.
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tumor growth. GOLPH3 shuttles between the Golgi appara-
tus and mitochondria to functionally promote mitochondrial 
biogenesis.34,35 Recently, Scott et al. identified GOLPH3 as an 
oncoprotein, which is genetically amplified in several tumors.35 
Moreover, GOLPH3 activates the autophagy inhibitor, 
mTOR.35 mTOR is a direct regulator of mitochondria function, 
and rapamycin (an mTOR1 inhibitor) decreases mitochondrial 
capacity and oxygen consumption,37 likely via the induction of 
autophagy.
Here, we overexpressed GOLPH3 in MDA-MB-231 breast 
cancer cells to examine the functional effects of autophagy 
resistance and enhanced mitochondrial biogenesis on tumor 
growth. Figure 10A shows that GOLPH3 was successfully sta-
bly expressed, as detected using antibodies directed against the 
HA-epitope tag. Then, we validated that GOLPH3 overexpres-
sion activates mTOR-signaling (Fig. 10B) and confers autoph-
agy resistance (Fig. 10B and C) using three autophagy markers 
(namely, cathepsin B, BNIP3 and LC3). Finally, GOLPH3 over-
expression in MDA-MB-231 cells also increased MitoTracker 
staining by > 2-fold, consistent with an increase in mitochondrial 
biogenesis and/or function (Fig. 11A).
Finally, we injected GOLPH3-overexpressing cancer cells 
into the flanks of athymic nude mice. At 4 weeks post-injection, 
GOLPH3 tumors showed a 3-fold increase in growth, relative 
to the vector-alone control (Fig. 11B). However, no significant 
increases in angiogenesis were noted, as visualized by CD31 
immunostaining (Fig. 11C).
Importantly, the effects of GOLPH3 on tumorigenesis are 
compartment-specific, as overexpression of GOLPH3 in hTERT 
fibroblasts increased MitoTracker activity by > 1.5-fold but did 
not significantly affect tumor growth when GOLPH3-fibroblats 
were co-injected with MDA-MB-231 breast cancer cells (Fig. S1).
Thus, we conclude that the tumor-promoting and tumor-
suppressing effects of autophagy are cell type-specific and are not 
intrinsic property of the process itself. Also, tumor suppressors 
(such as LKB1 and AMP-kinase) could function as tumor promot-
ers when activated in cancer-associated fibroblasts Therefore, the 
compartment-specific role of tumor suppressor and promoter genes 
should be carefully studied in both cancer cells and adjacent stro-
mal cells.
Discussion
Autophagy in the tumor microenvironment: Does stromal 
catabolism fuel anabolic tumor growth? Recently, we showed 
that a loss of Cav-1 expression in the tumor stroma predicts early 
tumor recurrence, lymph-node metastasis, tamoxifen resistance 
and overall poor clinical outcome in women with breast can-
cer.17,18 Molecular profiling of Cav-1-deficient tumor microenvi-
ronment in breast cancer patients demonstrates the induction of 
target genes associated with aging, DNA damage, inflammation 
and especially autophagy, all of which are known to be associ-
ated with exposure to hydrogen peroxide (due to activation of 
key transcription factors, namely, HIF1 and NFκB).38 Thus, 
one idea is that oxidative stress-induced catabolism in the tumor 
microenvironment fuels the anabolic growth of cancer cells. We 
Figure 3. DRAM activates autophagy in fibroblasts, resulting in loss of 
Cav-1 protein expression. Note that DRAM-overexpressing fibroblasts 
also showed a loss of Cav-1 expression, as predicted, likely due to the 
induction of autophagy. Immunoblotting with β-actin is shown as a 
control for equal protein loading.
which then drives autophagy when AMP levels rise due to mito-
chondrial dysfunction.30
To assess whether AMP-kinase activation in stromal fibro-
blasts is sufficient to promote tumor growth, we next generated 
hTERT-BJ1 fibroblasts overexpressing wild-type LKB1. As criti-
cal negative controls, we also generated matched fibroblast cell 
lines overexpressing a kinase-dead (KD) form of LKB1 (K78I) 
or the vector-alone control (pBABE-puro). Kinase-dead LKB1 
may be expected to show a dominant-negative phenotype, as it 
should retain the ability to bind to and sequester its substrate, 
AMP kinase.
Figure 7A shows that both forms of LKB1 (WT and KD) 
were well expressed in hTERT-BJ1 fibroblasts, although the KD 
mutant (K78I) showed higher steady-state expression levels. 
Importantly, wild-type LKB1 functionally induced the activa-
tion of AMP-kinase phosphorylation as seen by immunoblot 
analysis, with phospho-specific antibody probes (Fig. 7B), and 
was sufficient to upregulate autophagy markers (such as BNIP3 
and LC3-I/II) (Fig. 7C).
To determine whether autophagic fibroblasts with con-
stitutive AMP-kinase activation can promote tumor growth, 
LKB1-overexpressing fibroblasts were co-injected with MDA-MB-
231-GFP+ cells into the flanks of athymic nude mice (Fig. 8A). As 
predicted, autophagic fibroblasts overexpressing wild-type LKB1 
significantly promoted tumor growth (by ~2-fold), while fibro-
blasts expressing kinase-dead LKB1 dramatically retarded tumor 
growth (by > 2.5-fold) (Fig. 8B). Moreover, if we compare wild-
type vs. kinase-dead LKB1 fibroblast-driven tumor growth, there 
was a ~3–5-fold reduction in tumor growth in the absence of stro-
mal activation of AMP kinase. Importantly, these striking changes 
in tumor growth did not correlate with large increases or decreases 
in neo-vascularization, as measured by CD31 immunostaining, 
ruling out angiogenesis as the primary cause (Fig. 8C).
Consistent with the idea that AMP-kinase activation in 
cancer-associated fibroblasts is strictly required to promote 
tumor growth, recombinant expression of AMP-kinase isoforms 
(AMPK α1 or α2) alone in hTERT fibroblasts was not sufficient 
to promote tumor growth (Fig. 9). Thus, AMP-kinase activa-
tion, mediated by LKB1, is specifically required to generate this 
phenotype.
GOLPH3 confers autophagy resistance and promotes mito-
chondrial biogenesis in breast cancer cells, enhancing anabolic 
© 2012 Landes Bioscience.
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previously termed this new model of stromal-epithelial metabolic 
coupling the “autophagic tumor stroma model of cancer.” In 
accordance with this hypothesis, other laboratories have shown 
that the expression of autophagy-associated genes in the tumor 
stroma is associated with more aggressive tumor behavior and 
poor clinical outcome.39-41
Here, to genetically test this hypothesis, we chose to generate 
various pre-clinical models of autophagic cancer-associated fibro-
blasts via the overexpression of autophagy genes and AMP-kinase 
activators (DRAM and LKB1).
Autophagy (Beclin1, LAMP1 and Cathepsin B) and mitoph-
agy (BNIP3) genes were specifically upregulated by DRAM 
expression in hTERT-immortalized fibroblasts. Cav-1 protein 
expression and mitochondrial OXPHOS complexes were also 
downregulated in DRAM-overexpressing fibroblasts, reflecting 
Figure 5. DRAM-overexpressing fibroblasts show AMp-kinase activa-
tion. Mitochondrial dysfunction leads to increases in AMp levels (due to 
decreased Atp). thus, we examined the status of AMp-kinase activation. 
Note that AMp-kinase is indeed hyperactivated in DRAM-overexpress-
ing fibroblasts, consistent with a loss of mitochondrial function. Immu-
noblotting with β-actin is shown as a control for equal protein loading.
Figure 4. DRAM activates autophagy in fibroblasts, driving mitochondrial dysfunction. (A) oXpHoS immunoblotting. Given the upregulation of 
BNIp3 (a marker of mitophagy), we also investigated the status of mitochondrial oXpHoS (complexes I–V). Note that DRAM-overexpressing fibroblasts 
showed significant reductions in components of oXpHoS complexes I, III and IV, consistent with a mitophagy phenotype. Immunoblotting with 
β-actin is shown as a control for equal protein loading. (B) L-lactate production. hteRt fibroblasts were plated in 12-well dishes in complete media, at a 
cell density of 1 x 105 fibroblasts per well. the next day, the media was changed to fresh DMeM supplemented with 2% FBS. After 48 h, the media was 
collected, and L-lactate was immediately assayed using the enzyChrom L-lactate assay kit (BioAssay, Inc.), according to the manufacturer’s protocol. 
Cells were then washed, trypsinized and counted using a hemocytometer. Note that DRAM-overexpressing fibroblasts show a > 3-fold increase in 
L-lactate accumulation in the tissue culture media. (C and D) Ketone production. hteRt fibroblasts were plated in 12-well dishes in complete media 
at a cell density of 1 x 105 fibroblasts per well. the next day, the media was changed to fresh DMeM supplemented with 2% FBS. After 72 h, the media 
was collected and ketones were immediately assayed using a β-hydroxy-butyrate (β-HB) Assay Kit (Biovision, Inc.), according to the manufacturer’s 
protocol. Alternatively, cells were starved for 6 h by adding warm HBSS-supplemented with 40 mM HepeS. After starvation, the HBSS was collected 
and ketones were measured. Cells were washed, trypsinized and counted using a hemocytometer. Note that DRAM-overexpressing fibroblasts show a 
> 3-fold increase in ketone body accumulation in the tissue culture media (C), and this effect was accentuated further by starvation (D).
© 2012 Landes Bioscience.
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for the first time that LKB1 acts as a tumor promoter 
in cancer-associated fibroblasts.
These findings indicate that the specific role of 
tumor suppressors needs be re-evaluated according 
to their expression in a given cell-type or metabolic 
tumor compartment (e.g., stromal cells vs. epithelial 
cancer cells).
Mitochondrial biogenesis and autophagy resis-
tance in cancer cells promotes increased tumor 
growth. Next, we tested the hypothesis that mito-
chondrial biogenesis and autophagy resistance in 
epithelial cancer cells would also enhance anabolic 
tumor growth. For this purpose, we chose to overex-
press GOLPH3 in human breast cancer cells (MDA-
MB-231-GFP+). GOLPH3 is a recently discovered 
oncoprotein that activates the mTOR-signaling 
pathway.35 As predicted, GOLPH3-overexpressing 
MDA-MB-231 cells showed increased mTOR phos-
phorylation and significant reductions in both 
autophagy and mitophagy markers (LC3, Cathepsin 
B and BNIP3), consistent with the onset of autoph-
agy resistance. In addition, GOLPH3-overexpressing 
MDA-MB-231 cells also showed a 2.3-fold increase 
in MitoTracker activity, indicative of an increase in 
mitochondrial biogenesis and/or function. In support 
of the hypothesis that mitochondrial biogenesis and 
autophagy resistance will promote tumor aggressive-
ness, GOLPH3-overexpressing MDA-MB-231 cells 
showed a 3-fold increase in tumor growth. Thus, we 
demonstrate for the first time that GOLPH3 regulates 
both autophagy and mitochondrial activity. As such, 
increased mitochondrial biogenesis or function may 
protect cancer cells against the induction of autoph-
agy, by preventing AMP-kinase activation.
Our current hypothesis is also consistent with the 
general consensus view that cancer cells benefit from 
evading the autophagy (self-eating) response.43-45 There are two 
known molecular mechanism(s) that cancer cells use to drive 
autophagy resistance: (1) hyperactivation of mTOR signaling, 
which is a central network or pathway that can inhibit autophagy 
and (2) the deletion and/or suppression of autophagy-inducing 
genes, such as LKB1, Beclin1, PTEN, tuberous sclerosis complex 
(TSC) 1 and 2, DAPK-1 and wild-type p53.43-45
A schematic diagram summarizing our new findings is pre-
sented in Figure 12. Thus, targeting autophagy and/or mitochon-
drial function in cancer cells and the tumor microenvironment 
is an important strategy for the development of new prognos-
tic markers and novel therapeutic interventions. However, it is 
important to note that tumor suppressor genes can also promote 
tumor growth when overexpressed in the tumor stromal micro-
environment. Thus, interfering with “stromal-epithelial meta-
bolic coupling” will help in the fight against cancer, as it will 
“cut-off the fuel supply” to cancer cells.
Developing autophagy-based therapies for the treatment 
of cancer patients. The idea of targeting autophagy as a treat-
ment for human cancers has now been embraced by the medical 
the onset of autophagy/mitophagy and mitochondrial dysfunc-
tion. AMP-kinase activation was also observed, indicative of 
the onset of metabolic dysfunction. Most importantly, consis-
tent with our hypothesis, DRAM-overexpressing fibroblasts 
co-injected with MDA-MB-231 breast cancer cells showed a 
2-fold increase in tumor growth relative to vector-alone control 
fibroblasts.
Quantitatively similar results were obtained by constitu-
tive activation of AMP kinase via overexpression of LKB1, its 
upstream activator. LKB1 normally phosphorylates AMP-
kinase-α on Thr-172, which initiates the activation of several 
metabolic pathways, such as autophagy, mitophagy and glycoly-
sis, during cellular stress.28,42 Here, we generated constitutively 
autophagic fibroblasts by overexpressing wild-type (WT) LKB1. 
As two critical negative control(s), we also generated (1) fibro-
blasts overexpressing a kinase-dead (KD) form of LKB1, as well 
as (2) vector-alone fibroblasts. Strikingly, fibroblasts overexpress-
ing WT-LKB1 increased tumor growth by ~2-fold, relative to 
the vector-alone control. Conversely, fibroblasts overexpressing 
KD-LKB1 reduced tumor growth by ~2.5-fold. Thus, we show 
Figure 6. DRAM-overexpressing fibroblasts enhance tumor growth, without a 
dramatic increase in angiogenesis. (A) DRAM-overexpressing fibroblasts were 
co-injected together with breast cancer cells (MDA-MB-231-GFp+) into the flanks of 
athymic nude mice flank. At 4 weeks post-injection, tumors grown in the presence 
of DRAM fibroblasts showed an ~2-fold increase in tumor growth (as measured by 
either tumor weight or volume). p-values are as shown. n = 10 per experimental 
group. (B) Although tumors grown with DRAM fibroblasts show a slight increase in 
CD31-positive vessel density (~18%), this small difference could not account for the 
observed 2-fold increase in tumor growth. thus, our data are more consistent with 
the hypothesis that catabolism in the tumor stroma can “fuel” the anabolic growth 
of cancer cells via stromal-epithelial metabolic coupling.
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oncology community. However, we show here that the 
regulation of autophagy in tumors is highly celltype- and 
compartment-specific.
More specifically, our current findings show that 
autophagy induction in the tumor microenvironment pro-
motes tumor growth, while autophagy resistance in can-
cer cells also enhances tumor growth. Thus, inhibition of 
autophagy in the tumor microenvironment should reduce 
tumor growth, while induction of autophagy in cancer 
cells should also inhibit tumor growth. These findings 
explain the well-known “autophagy paradox” of cancer 
therapy, that both autophagy inhibitors (chloroquine) and 
autophagy inducers (rapamycin) can prevent or signifi-
cantly reduce tumor growth.8,9
Rapamycin is an antibiotic that has been found to 
inhibit mTOR1 and induce autophagy.46,47 Analogs of 
rapamycin, temsirolimus and everolimus, have been 
approved to treat renal cell carcinoma and mantle cell lym-
phoma.48 Also, GDC-0941 and NVP-BEZ235 are dual 
inhibitors of mTOR1 and PI3K, which block the feed-
back loop resulting from mTOR1 inhibition.49 These two 
Figure 7. LKB1 activates AMp kinase in fibroblasts, resulting in the onset of autophagy. to determine if AMp-kinase activation in stromal fibroblasts is 
sufficient to promote tumor growth, we generated hteRt-BJ1 fibroblasts overexpressing wild-type LKB1. As critical negative controls, we also gener-
ated matched fibroblast cell lines overexpressing a kinase-dead (KD) form of LKB1 (K78I), or the vector-alone control (pBABe-puro). (A) Note that both 
forms of LKB1 (Wt and KD) were well-expressed in hteRt-BJ1 fibroblasts, although the KD mutant (K78I) showed higher steady-state expression levels. 
(B) Wild-type LKB1 functionally induced the activation of AMp-kinase phosphorylation as seen by immunoblot analysis, with phospho-specific anti-
body probes. (C) Wild-type LKB1 was sufficient to upregulate autophagy markers (such as BNIp3 and LC3-I/II). In (A–C), immunoblotting with β-actin is 
shown as a control for equal protein loading.
Figure 8. LKB1-mediated AMp-kinase activation in cancer-
associated fibroblasts drives autophagy and promotes tumor 
growth. to determine whether autophagic fibroblasts with 
constitutive AMp-kinase activation can promote tumor growth, 
LKB1-overexpressing fibroblasts were co-injected with MDA-
MB-231-GFp+ cells into the flanks of athymic nude mice. As 
predicted, autophagic fibroblasts overexpressing wild-type 
(Wt) LKB1 significantly promoted tumor growth (by ~2-fold), 
while fibroblasts expressing kinase-dead (KD) LKB1 dramatically 
retarded tumor growth (by > 2.5-fold) (A and B). p-values are as 
shown. n = 10 per experimental group. (A) the time course of 
tumor growth (volume) is shown up to 3.5 weeks post-injection. 
(B) tumor growth (weight and volume) is shown after tumor ex-
cision, on day 25 post-injection. (C) these striking changes in tu-
mor growth did not correlate with large increases or decreases 
in neo-vascularization, as measured by CD31 immunostaining, 
ruling out angiogenesis as the primary cause.
© 2012 Landes Bioscience.
Do not distribute.
2552 Cell Cycle Volume 11 Issue 13
(DMEM), supplemented with 10% fetal bovine 
serum in a 37°C humidified atmosphere contain-
ing 5% CO
2
, unless otherwise noted.
Cell line derivation. Lentiviral vectors. Lentiviral 
particles were produced after 48 h of transfecting the 
GeneCopoeia 293Ta lentiviral packaging cell line 
with lentiviral plasmids [EX-NEG-Lv105 (puro)] 
(empty vector), DRAM (EX-W1855-Lv105), 
AMPK-alpha1 559-a.a. (EX-H0271-Lv105), 
AMPK-alpha1 574-a.a. (EX-T8424-Lv105), or 
AMPK-alpha2 (EX-C0433-Lv105) (all obtained 
from GeneCopoeia, Inc.), using the Lenti-Pac 
HIV Expression Packing Kit (GeneCopoeia, Inc.), 
according to manufacturer’s recommendations. 
Human immortalized fibroblasts were transduced 
by lentivirus particles in the presence of 5 μg/ml of 
Polybrene (Santa Cruz Biotech). Transduced cells 
were selected with 1.5 μg/ml of puromycin.
Retroviral vectors. Retroviral plasmids pBABE-
puro (empty vector), LKB1 (pBABE-FLAG-LKB1, 
Plasmid #8592), LKB1-KD (pBABE-FLAG-KD 
LKB1, Plasmid #8593) and GOLPH3 (pBABE-
HA-GOLPH3, Plasmid #21687) (all obtained 
from Addgene Inc.) were transfected into the 
Phoenix Amphotropic packaging cell line using the FuGene6 
reagent (Roche Molecular Biochemicals) according to the manu-
facturer’s instructions. After 48 h, virus-containing medium was 
passed through a 0.45 μm filter and added to hTERT-BJ1 or 
MDA-MB-231-GFP cells, in the presence of 5 μg/ml Polybrene. 
Transduction was repeated the next day. Transduced cells were 
selected in the presence of 1.5 μg/ml (for hTERT-BJ1) and 2.0 
μg/ml (for MDA-MB-231-GFP+) puromycin.
Immunoblot assays. Protein lysates were obtained by cell 
scraping into lysis buffer (10 mM Tris, pH 7.5, 150 mM NaCl, 
1% Triton X-100 and 60 mM n-octylglucoside) containing pro-
tease inhibitors (Boehringer Mannheim). Samples were then 
incubated on a rotating platform at 4°C and were centrifuged at 
12,000x g for 10 min (at 4°C) to remove insoluble debris. Protein 
concentrations were analyzed using the BCA reagent (Pierce). 
Samples were separated by SDS-PAGE (10%-acrylamide) and 
transferred to nitrocellulose. All subsequent wash buffers con-
tained 10 mM Tris, pH 8.0, 150 mM NaCl, 0.1% Tween 20, 
which was supplemented with 5% nonfat dry milk (Carnation) 
for the blocking solution and 1% bovine serum albumin (Sigma) 
for the antibody diluent. Horseradish peroxidase-conjugated sec-
ondary antibodies were used to visualize bound primary antibod-
ies with an ECL detection kit (Pierce).
Immunofluorescence. Cancer cells (MDA-MB-231) and 
fibroblasts (hTERT-BJ1) were plated onto coverslips in 12-well 
plates for 48 h in DMEM supplemented with 10% Nu serum. 
Then, cells were rinsed with PBS containing 0.1 mM CaCl
2
 and 
1 mM MgCl
2
 (PBS/CM) and fixed with 2% paraformaldehyde 
in PBS/CM for 30 min. After fixation, cells were washed three 
times with PBS/CM and permeabilized with IF buffer (PBS/CM 
with 0.1% Triton-X100 and 0.2% bovine serum albumin) for 
10 min. Then, fixed cells were quenched with 50 mM NH
4
Cl in 
Figure 9. overexpression of AMp-kinase isoforms in fibroblasts is not sufficient to 
promote tumor growth. AMp-kinase overexpressing fibroblasts were co-injected with 
MDA-MB-231-GFp+ cells into the flanks of athymic nude mice. Note that recombinant 
expression of AMp-kinase isoforms (AMpK α1 or α2) alone in hteRt fibroblasts was not 
sufficient to promote tumor growth. thus, AMp-kinase activation, mediated by LKB1, is 
specifically required to enhance tumor growth. the functional effects of expression of 
two different isoforms of AMpK α1 was examined (559 amino acids vs. 574 amino acids). 
NS, not significant. n = 10 per experimental group.
promising drugs have now entered phase II trials for breast cancer 
treatment.49 Interestingly, temsirolimus and hydroxychloroquine 
(HCQ) have been used in a phase I trial for treating refractory 
metastatic solid tumors (http://clinicaltrials.gov/ct2/show/
NCT00909831).
Hydroxy-chloroquine (HCQ; an anti-malarial drug) inhib-
its autophagy by disturbing the vacuolar H+ ATPase respon-
sible for lysosomes acidification.50 A chloroquine-based clinical 
trial for the treatment of early human breast cancers (DCIS 
lesions) is now ongoing: http://clinicaltrials.gov/ct2/show/
NCT01023477.
Materials and Methods
Materials. Antibodies were purchased from the following com-
mercial sources: Anti-DRAM [# sc-98654 (H-128); Santa Cruz 
Biotech], anti-Cav-1 [#sc-894 (N-20); Santa Cruz Biotech], 
anti-Beclin1 (for immuno-blot #NBP1-00085, Novus; for 
immunostaining #2026-1, Epitomics), anti-LAMP1 [#sc-17768 
(E-5); Santa Cruz Biotech], anti-BNIP-3 (#ab10433; Abcam), 
anti-Cathepsin B (#sc-13985 (FL-339); Santa Cruz Biotech), 
anti-OXPHOS (#MS601; Mitosciences), anti-β actin (#A5441, 
Sigma), anti-phospho-AMPK (#2531, Cell Signaling), anti-
AMPK (#2532, Cell Signaling), anti-LKB (#sc-32245 (Ley 37D/
G6); Santa Cruz Biotech), anti-mTOR (#2983; Cell Signaling), 
anti-phospho-mTOR (#2971; Cell Signaling) and anti-HA 
(#16B12; Covance). Other reagents were purchased as follows: 
Hoechst-33258 nuclear stain was from Sigma and Anti-fade 
reagent (#S2828) was from Invitrogen.
Cell cultures. MDA-MB-231 cells (a human breast triple neg-
ative cell line) and hTERT-BJ1 cells (an immortalized fibroblast 
cell line) were cultured in Dulbecco’s modified Eagle’s medium 
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Figure 10. GoLpH3 overexpression in breast cancer cells confers mtoR activation and autophagy resistance. We overexpressed GoLpH3 in MDA-
MB-231 breast cancer cells, to examine its functional effects on mtoR activation and autophagy resistance. (A) Note that GoLpH3 was successfully sta-
bly expressed in MDA-MB-231 cells, as detected using antibodies directed against the HA-epitope tag. (B) Under basal cell culture conditions, GoLpH3 
activates mtoR hyper-phosphorylation and a loss of cathepsin B expression. (C) Under conditions of starvation [4 h in HBSS (40 mM HepeS, pH 7.2, in 
Hank’s Balanced Salt Solution)], GoLpH3 confers autophagy resistance, as evidenced by a loss of BNIp3 and LC3-I/II expression. In (A–C), immunoblot-
ting with β-actin is shown as a control for equal protein loading.
Figure 11. GoLpH3 overexpression promotes mitochondrial biogenesis in breast cancer cells, enhancing anabolic tumor growth. (A) GoLpH3 over-
expression in MDA-MB-231 cells increased Mitotracker staining by > 2-fold, consistent with an increase in mitochondrial biogenesis and/or function. 
(B) We injected GoLpH3-overexpressing MDA-MB-231 cells into the flanks of athymic nude mice. At 4 weeks post-injection, GoLpH3 tumors showed 
a 3-fold increase in growth, relative to the vector-alone control. p-values are as shown. n = 10 per experimental group. (C) No significant increases in 
angiogenesis were noted, as visualized by CD31 immunostaining.
PBS/CM for 10 min, rinsed and incubated with anti-beclin-1 or 
anti-LAMP1 antibodies for 1 h at room temperature. Cells were 
washed with IF buffer and incubated with fluorescent secondary 
antibodies (Molecular Probes) for 30 min. After washing, cells 
were incubated with Hoechst-33258 for nuclear staining, rinsed 
and mounted with ProLong Gold anti-fade (Molecular Probes). 
Images were acquired with a Zeiss LSM510 Meta confocal micro-
scope system and analyzed with Zeiss LSM Browser.
Mitochondrial activity studies. We stained cell lines with 
MitoTracker Orange (CMTMRos; cat #M7510, Invitrogen, 
Inc.) to measure mitochondrial activity, as stain accumulation 
is dependent upon an intact mitochondrial membrane poten-
tial. Cells were cultured for 2 d in DMEM supplemented with 
10% Nu serum. After 2 d, the cells were then incubated with 
pre-warmed MitoTracker staining solution (diluted in serum-
free DMEM to a final concentration of 25 nM) for 10 min at 
37°C. All subsequent steps were performed in the dark. Cells 
were washed in PBS, trypsinized and re-suspended in 300 μL of 
Binding Buffer (BD Biosciences). Cells were then analyzed by 
FACS. Data analysis was performed using FlowJo 8.8 software.
Pre-clinical animal studies. All animals were maintained in a 
pathogen-free environment/barrier facility at the Kimmel Cancer 
Center at Thomas Jefferson University under National Institutes 
of Health (NIH) guidelines. All animal protocols were approved 
by the Institutional Animal Care and Use Committee (IACUC). 
Tumor cells (MDA-MB-231-GFP+; 1 x 106 cells) were injected 
alone or co-injected with hTERT-BJ1 fibroblasts (3 x 105 cells) 
in 100 μl of sterile PBS into the flanks of athymic NCr nude 
mice (NCRNU; Taconic Farms; 6–8 weeks of age). Mice were 
sacrificed at 3–4 weeks post-injection; tumors were excised to 
determine their weight and size, using electronic calipers. Tumor 
volumes were calculated using the formula V = (x2y)/2, where V 
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day, the media was switched to DMEM containing 2% FBS. 
After 48 h, the media was collected, and the concentration of 
L-lactate was measured. Results were normalized for total cell 
number.
Ketone body production. Cells were seeded in 12-well plates 
in DMEM supplemented with 10% FBS. The next day, the 
media was switched to DMEM without red-phenol, contain-
ing 2% FBS. After 72 h, the media was collected, and the keto-
acid concentration was measured according the manufacturer’s 
instructions using the β-Hydroxy-butyrate (β-HB) Assay Kit 
(Biovision, #K632). Results were normalized for either total cell 
number. In some experiments, Hank’s balanced salt solution 
(HBSS) supplemented with 40 mM Hepes was used to initiate 
cell starvation.
Statistical analysis. Statistical significance was examined 
using the Student t-test. Values of p < 0.05 were considered 
significant.
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Figure 12. Autophagy and two-compartment tumor metabolism: 
Defining the roles of DRAM, LKB1 and GoLpH3. DRAM and LKB1 acti-
vate AMp-kinase in cancer-associated fibroblasts, driving autophagy, 
mitophagy and mitochondrial dysfunction. Conversely, GoLpH3 
expression in cancer cells mediates autophagy resistance, likely via 
the induction of mitochondrial biogenesis, or the enhancement of 
mitochondrial function. thus, compartment-specific regulation of 
autophagy results in a “parasitic” form of stromal-epithelial metabolic 
coupling. HQ, hydroxy-chloroquine; RA, rapamycin analogs. Both chlo-
roquine and rapamycin analogs could functionally disrupt metabolic 
coupling, by simultaneously turning “on” or “off” autophagy in both 
cellular compartments (cancer cells and stromal fibroblasts). CAFs, 
cancer-associated fibroblasts.
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